Information:
Error:
ID
34179
Description
Phase I/II Trial of Stereotactic Body Radiotherapy With Concurrent Fixed Dose Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma: Dose Limiting Toxicity and Abscopal Effect.; ODM derived from: https://clinicaltrials.gov/show/NCT02334709
Link
https://clinicaltrials.gov/show/NCT02334709
Keywords
Versions (1)
- 1/15/19 1/15/19 -
Copyright Holder
GSK group of companies
Uploaded on
January 15, 2019
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Carcinoma, Renal Cell NCT02334709
Eligibility Carcinoma, Renal Cell NCT02334709
- StudyEvent: Eligibility
Similar models
Eligibility Carcinoma, Renal Cell NCT02334709
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
ID.1
Item
signed informed consent
boolean
ID.2
Item
diagnosis of rcc with clear-cell component histology
boolean
ID.3
Item
at least 3 extracranial measurable metastatic lesions per recist
boolean
ID.4
Item
karnofsky performance score >60
boolean
ID.5
Item
patients should have undergone cytoreductive treatment of their rcc at least 6 weeks prior to inclusion
boolean
ID.6
Item
patients should have adequate organ function for tki treatment.
boolean
ID.7
Item
prior systemic treatment for rcc
boolean
ID.8
Item
uncontrolled central nervous metastases
boolean
ID.9
Item
prior radiotherapy interfering with sbrt
boolean
ID.10
Item
any disorder precluding understanding of trial information.
boolean